ArticleScientific reports2025
Lactate to hemoglobin ratio predicts short and long term mortality in critically ill patients with Gastrointestinal bleeding.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactate-to-Hemoglobin Ratio as a Predictor of 30-Day Mortality in Patients with Non-Variceal Acute Upper Gastrointestinal Bleeding.Diagnostics (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the lactate-to-hemoglobin ratio (LHR) as a novel biomarker for predicting short-term and long-term mortality in critically ill patients with gastrointestinal bleeding (GIB). Data from 1387 patients in the MIMIC - IV database were analyzed. Results showed that LHR was significantly associated with 7-day, 28-day and 365-day mortality. It had moderate discriminative ability in predicting mortality, with area under the curve (AUC) values ranging from 0.637 to 0.694. Compared with traditional markers and scoring systems, LHR has certain advantages. However, the study has limitations such as a retrospective design and single - center data. In conclusion, LHR shows promise as a prognostic tool for GIB patients, but further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.